• Carboplatin Resistance: A Stemness-Aware Assay Guide

  2026-08-26

  Carboplatin is a platinum-based DNA synthesis inhibitor with broad utility in preclinical oncology research. This guide presents a resistance-aware strategy that connects DNA damage assays with cancer stem-like phenotypes and the IGF2BP3–FZD1/7 axis.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-08-26

  Breen and colleagues developed a drug-sensitized Saccharomyces cerevisiae platform that detects TOR inhibitors at substantially lower concentrations than conventional yeast backgrounds. The system recovered activity from established inhibitors, resolved AZD8055 sensitivity that was otherwise undetectable, identified aminophylline as a TOR1-dependent growth inhibitor, and found no evidence of TOR inhibition for several additional test compounds, including nebivolol.

• Urolithin A and the Metabolic Logic of Fibrosis

  2026-08-25

  A translational perspective on how Urolithin A may connect mitochondrial quality control with the glutamine-dependent biology of hepatic stellate cells, alongside practical guidance for validating this hypothesis and positioning the compound in mitochondrial, aging, and fibrosis research.

• Bacitracin (B1670): Practical Research Protocol

  2026-08-25

  Bacitracin (B1670) provides a defined, quality-controlled peptide antibiotic format for antibacterial research involving bacterial cell wall and peptidoglycan synthesis disruption. This guide covers preparation, assay controls, and QC boundaries; the material is for scientific research only and is not intended for diagnostic, clinical, or medical use.

• Epigenetic Immune Signatures in Melanoma

  2026-08-24

  Anichini et al. systematically compared immune-related transcriptional programs induced by five epigenetic drug classes in melanoma and identified guadecitabine as the strongest activator of innate immune signatures. The study connects tumor-cell epigenetic remodeling with clinical biopsy data and provides a framework for selecting epigenetic agents for combination immunotherapy while clarifying why activity is regulator-specific.

• Belinostat (PXD101): From HDAC to Splicing

  2026-08-24

  Belinostat (PXD101) offers translational researchers a practical way to interrogate how histone deacetylase inhibition may connect chromatin state, spliceosome function, cell-cycle control, and DNA-damage response. This article frames the compound as a mechanistic research tool rather than a standalone cytotoxic readout, integrating evidence from bladder and prostate models with recent findings on SmD2 acetylation and PARP inhibitor sensitivity in hepatocellular carcinoma.

• TDRD9 siRNA Nanoparticles in Pseudomonas Lung Injury

  2026-08-23

  This study identifies TDRD9 as a regulator of neutrophil cuproptosis during Pseudomonas aeruginosa lung infection and develops hyaluronic acid-coated peptide nanoparticles for siRNA delivery. Across patient-derived samples, mouse models, adoptive-transfer experiments, and human lung organoids, TDRD9 silencing reduced neutrophil accumulation, pulmonary inflammation, and tissue injury while improving infection-associated outcomes.

• Gemcitabine HCl: Mechanism and Research Workflow

  2026-08-22

  Gemcitabine HCl is a deoxycytidine analog used to study DNA replication inhibition and apoptosis induction in cancer cells. Vendor-reported pancreatic cancer cell assays show IC50 values from 12 nM to 50 nM, while KPC mouse studies support longitudinal MRI-based assessment of tumor response.

• Mubritinib (TAK 165): Complex I Research Workflows

  2026-08-22

  Mubritinib (TAK 165) is most informative when treated as a mitochondrial complex I probe rather than simply a HER2 tool. This workflow guide connects dose selection, ROS and apoptosis readouts, cisplatin combination studies, and AML or PEL applications while emphasizing practical controls and troubleshooting.

• ECL Chemiluminescent Substrate Kit for Immunoblotting

  2026-08-21

  The ECL Chemiluminescent Substrate Detection Kit supports horseradish peroxidase (HRP) chemiluminescence for sensitive immunoblotting on nitrocellulose and PVDF membranes. Its reported low-picogram sensitivity, 6–8-hour signal duration, and 24-hour working-reagent stability are useful for low-abundance protein workflows, subject to antibody and imaging optimization.

• ONX-0914: Reading Immunoproteasome Biology

  2026-08-20

  ONX-0914 (PR-957) is a selective LMP7 inhibitor for dissecting immunoproteasome-dependent cytokine signaling. This article connects autoimmune assay design with a key antiviral discovery while emphasizing causal interpretation, controls, and evidence limits.

• LY2603618: Chk1 Inhibition Beyond the Checkpoint

  2026-08-20

  LY2603618 offers translational researchers a precise way to interrogate Chk1-dependent checkpoint control, replication stress, and chemotherapy sensitization. This article connects its preclinical profile with emerging PARP1-trapping biology and outlines a practical framework for biomarker-led DNA damage response research.

• NS7a, Apoptosis, and IFN-λ Suppression in SADS-CoV

  2026-08-19

  The reference study identifies NS7a as a major SADS-CoV apoptosis-inducing protein and maps an AIFM1–caspase-6–caspase-3 pathway that cleaves IRF3 and suppresses type III interferon production. Its cell and piglet experiments connect apoptosis with enhanced viral replication, while inhibitor treatment provides a mechanistic basis for testing caspase-directed antiviral strategies.

• Metronidazole Research Workflows

  2026-08-19

  Metronidazole supports two complementary research directions: anaerobic bacteria targeting and transporter-mediated drug interaction studies. This workflow-focused guide shows how to prepare the compound, design OAT3 and uptake assays, interpret microbiology endpoints, and troubleshoot reproducibility.

• Itraconazole as a Candida Biofilm Probe

  2026-08-18

  Itraconazole is a triazole antifungal agent with value beyond routine growth inhibition. This article shows how to use it as a mechanistic probe for Candida biofilm resistance, PP2A-regulated autophagy, CYP3A4 interaction studies, and assay design.

8009 records 1/534 page Next 12345 下5页 Last page